Skip to main content
Premium Trial:

Request an Annual Quote

Lucira Health Files for $115M IPO

NEW YORK — Lucira Health, a developer of an instrument-free, low-cost molecular diagnostics platform for infectious disease testing, filed for a $115 million initial public offering with the US Securities and Exchange Commission last week.

In the filing, the Emeryville, California-based company said it intends to float an undisclosed number of shares on the Nasdaq at a yet-to-be-determined price under the ticker symbol LHDX. BofA Securities, LifeSci Capital, and William Blair are underwriting the IPO.

Lucira was founded in 2013, originally under the name DiAssess, to develop single-use, portable test kits for infectious diseases that can be administered in both healthcare settings and at home.

In November, the company received Emergency Use Authorization from the US Food and Drug Administration for the Lucira COVID-19 All-in-One Test Kit, a rapid, at-home, real-time loop-mediated isothermal amplification (LAMP) SARS-CoV-2 test available by prescription that runs on a handheld batter-powered device. An over-the-counter version of the test is expected to be submitted to the FDA later this year. 

Lucira is also developing a prescription SARS-CoV-2/influenza combination test that is expected to be submitted to the FDA in 2022 and an over-the-counter flu test that is slated for FDA submission in 2024. The flu test is being developed with funding from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

In its SEC filing, Lucira said that it intends to use the proceeds of the IPO to support its manufacturing activities, to establish commercial operations including a sales and marketing team, and for working capital and general corporate purposes.

Lucira, which raised $15 million in Series B funding in 2019, said in the filing that it had $68.3 million in cash as of Sept. 30, 2020. It recorded $16.1 million in R&D costs for the first nine months of 2020, with SG&A costs totaling $3.2 million. Its net loss for this nine-month period totaled $20.2 million. The firm has generated no revenues to date.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.